To include your compound in the COVID-19 Resource Center, submit it here.

Have approvals, will travel

For the second quarter in a row, approvals out-numbered significant late-stage setbacks by nearly 2-1. But unlike the first quarter, in which good news didn't lure investors to the sector, the recent glut of good

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers